Pete SessionsSell
AbbVie Inc. Common Stock · Transaction Sep 14, 2026 · Filed Sep 18, 2026 · $15,001 to $50,000
NEW YORK STOCK EXCHANGE, INC. · ABBV
+0.71% · +$2.02 · Vol Not reported
Market closed · last close 4:00 PM ET · price as of 16:00:00 ET
AbbVie Inc
Biotechnology
$285.42
Follow $ABBV
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $ABBV by emailVeridion Score
BETAHIGH CONF · 6 of 6 factors measuredFri Oct 16 · last completed session · Markets closed · resumes Mon 9:30 ET · ABBV
MethodologyABBV
AbbVie Inc
Fri Oct 16 · last completed session · Markets closed · resumes Mon 9:30 ET
Upper range
Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
63/ 100
Veridion Score
Upper range · HIGH confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Confidence: HIGH · 6 of 6 factors measured · Fri Oct 16 · last completed session · Markets closed · resumes Mon 9:30 ET
AI Analysis
SovereignWhy is ABBV moving today?
Sovereign unlock connects news, insider activity, analyst moves, and available price action.
About AbbVie Inc
PHARMACEUTICAL PREPARATIONSListed since
2012
Employees
57K
Country
US
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$283.61
Day high
$286.64
Day low
$282.95
Previous close
$283.40
52W high
$286.64
-0.43% from high
52W low
$197.38
99% of range
Market cap
$504.4B
P/E
79.93×
EPS
$3.56
Beta
-0.68
Shares out
1.8B
Avg volume
4.8M
VWAP
$283.40
Last session
Price history computed in-house
1W
+3.24%
1M
+8.13%
3M
+12.65%
1Y
+24.33%
YTD
+24.92%
SMA 50 $262.45 · above
SMA 200 $233.95 · above
52W position 99%
ABBV overview
Veridion Score
63
Registered · 2026-10-16
6 of 6 factors measured
Latest receipt rows
5
Pete Sessions · Sale
13F holders
3
Geode Capital Management, LLC
Receipt-backed holder profiles
SEC industry peers
ABBV peers
Related filings and maps
Public disclosures
Congress activity in ABBV
48 filers · 78 buys · 72 sells (3 labeled S (partial)) · 1 other · Jan 1, 2013 to Sep 14, 2026 · House 131 / Senate 20
All available history · Latest 5 of 151 lines · Read Oct 18, 2026, 9:13 AM UTC
Official filing ↗
AbbVie Inc. Common Stock · Transaction May 5, 2026 · Filed Jun 3, 2026 · $1,001 to $15,000
AbbVie Inc. Common Stock · Transaction Dec 18, 2025 · Filed Jan 15, 2026 · $1,001 to $15,000
Julia LetlowSell
AbbVie Inc. Common Stock · Transaction Dec 8, 2025 · Filed Jan 13, 2026 · $1,001 to $15,000
AbbVie Inc. Common Stock · Transaction Nov 13, 2025 · Filed Dec 11, 2025 · $1,001 to $15,000
Federal contracts
ABBV contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for ABBV in this window.
Lobbying spend
ABBV lobbying filings, year to date.
Registered lobbying filings matched to AbbVie Inc.
Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for ABBV in this window.
Analyst ratings
Sovereign unlock shows available analyst consensus for ABBV.